Elevated C-reactive protein levels predict worsening prognosis in Chinese patients with first-onset stroke

Abstract

The role of high sensitivity C-reactive protein (hsCRP) in predicting prognosis after stroke in the Asian population has not been investigated. We hypothesized that elevated levels of hsCRP were associated with worsening prognosis after stroke in Chinese patients. Two hundred and ninety consecutive patients with first-onset stroke and 290 age- and gender-matched control subjects without any cerebrovascular disease were enrolled for study. Plasma hsCRP level was detected and subsequent vascular events and death were recorded in both groups over a 5-year period. Compared to control group, patients presenting with stroke had higher plasma hsCRP level (3.3 ± 3.8 vs 1.3 ± 2.2 mg/L, P< 0.01). Furthermore, in the group of patients with stroke, the mean plasma hsCRP level was higher in patients who developed subsequent vascular diseases or died as compared with the patients without further complications (4.4 ± 4.3 vs 2.7 ± 3.3 mg/L, P< 0.01). Compared to the lowest tertile of hsCRP level, the relative risk for vascular events or death in stroke patients was 2.91 in the highest tertile of hsCRP (95% CI, 1.54–5.50, P = 0.001). This increase in relative risk for vascular events or death in stroke patients continued after adjustment for age, sex and other cardiovascular risk factors such as hypertension and diabetes (OR: 2.771, 95% CI: 1.367–5.617, P = 0.005). These findings indicate that increased hsCRP level is associated with worsening prognosis after stroke in Chinese patients and suggests that inflammation is correlated with stroke outcome.

Keywords

C-reactive protein / inflammation / stroke

References

[1] LibbyP. Inflammation in atherosclerosis. Nature, 2002, 420(6917): 868-874

[2] BlakeG J, RidkerP M. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med, 2002, 252(2): 283-294

[3] EngstromG, HedbladB, StavenowL, TydenP, LindP, JanzonL, LindgardeF. Fatality of future coronary events is related to inflammation-sensitive plasma proteins: A population-based prospective cohort study. Circulation, 2004, 110(1): 27-31

[4] RidkerP M, HennekensC H, BuringJ E, RifaiN. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 2000, 342(12): 836-843

[5] DaneshJ, WheelerJ G, HirschfieldG M, EdaS, EiriksdottirG, RumleyA, LoweG D O, PepysM B, GudnasonV. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med, 2004, 350(14): 1387-1397

[6] KoenigW, SundM, FrohlichM, FischerH G, LowelH, DoringA, HutchinsonW L, PepysM B. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the monica (monitoring trends and determinants in cardiovascular disease) augsburg cohort study, 1984 to 1992. Circulation, 1999, 99(2): 237-242

[7] RidkerP M, CushmanM, StampferM J, TracyR P, HennekensC H. Plasma concentration of c-reactive protein and risk of developing peripheral vascular disease. Circulation, 1998, 97(5): 425-428

[8] RostN S, WolfP A, KaseC S, Kelly-HayesM, SilbershatzH, MassaroJ M, D'AgostinoR B, FranzblauC, WilsonP W. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke, 2001, 32(11): 2575-2579

[9] ThompsonS G, KienastJ, PykeS D, HaverkateF, van de LooJ C. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med, 1995, 332(10): 635-641

[10] HaverkateF T S, PykeS D, GallimoreJ R, PepysM B. Production of c-reactive protein and risk of coronary events in stable and unstable angina. European concerted action on thrombosis and disabilities angina pectoris study group. Lancet, 1997, 349(9050): 462-466

[11] LiuzzoG, BiasucciL M, GallimoreJ R, GrilloR L, RebuzziA G, PepysM B, MaseriA. The prognostic value of c-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med, 1994, 331(7): 417-424

[12] HanssonG K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med, 2005, 352(16): 1685-1695

[13] RidkerP M, CushmanM, StampferM J, TracyR P, HennekensC H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med, 1997, 336(14): 973-979

[14] MegaJ L, MorrowD A, CannonC P, MurphyS, CairnsR, RidkerP M, BraunwaldE. Cholesterol, c-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. J Thromb Thrombolysis. 2006, 22(1): 71-76

[15] RidkerP M, CannonC P, MorrowD, RifaiN, RoseL M, McCabeC H, PfefferM A, BraunwaldE. the Pravastatin or Atorvastatin Evaluation and Infection Therapy Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med, 2005, 352(1): 20-28

[16] Di NapoliM, PapaF, BocolaV. C-reactive protein in ischemic stroke: An independent prognostic factor. Stroke, 2001, 32(4): 917-924

[17] MuirK W, WeirC J, AlwanW, SquireI B, LeesK R. C-reactive protein and outcome after ischemic stroke. Stroke, 1999, 30(5): 981-985

[18] ElkindM S, TaiW, CoatesK, PaikM C, SaccoR L. High-sensitivity c-reactive protein, lipoprotein-associated phospholipase a2, and outcome after ischemic stroke. Arch Intern Med, 2006, 166(19): 2073-2080

[19] TorzewskiJ T M, BowyerD E, FrohlichM, KoenigW, WaltenbergerJ, FitzsimmonsC, HombachV. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol, 1998, 18(9): 1386-1392

[20] ZhangY X, CliffW J, SchoeflG I, HigginsG. Coronary c-reactive protein distribution: Its relation to development of atherosclerosis. Atherosclerosis, 1999, 145(2): 375-379

[21] ChangM K, BinderC J, TorzewskiM, WitztumJ L. From the cover: C-reactive protein binds to both oxidized ldl and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. PNAS, 2002, 99(20): 13043-13048

[22] PasceriV, WillersonJ T, YehE T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation, 2000, 102(18): 2165-2168

[23] DevarajS, XuD Y, JialalI. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: Implications for the metabolic syndrome and atherothrombosis. Circulation, 2003, 107(3): 398-404

[24] ZwakaT P, HombachV, TorzewskiJ. C-reactive protein-mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis. Circulation, 2001, 103(9): 1194-1197

[25] VenugopalS K, DevarajS, YuhannaI, ShaulP, JialalI. Demonstration that c-reactive protein decreases enos expression and bioactivity in human aortic endothelial cells. Circulation, 2002, 106(12): 1439-1441

[26] AronowskiJ, HallC E. New horizons for primary intracerebral hemorrhage treatment: Experience from preclinical studies. Neurol Res, 2005, 27(3): 268-279

[27] XueM, Del BigioM R. Immune pre-activation exacerbates hemorrhagic brain injury in immature mouse brain. J Neuroimmunol, 2005, 165(1-2): 75-82

[28] ZhangX F, AttiaJ, D'EsteC, YuX H. Prevalence and magnitude of classical risk factors for stroke in a cohort of 5092 Chinese steelworkers over 13.5 years of follow-up. Stroke, 2004, 35(5): 1052-1056

[29] LeppalaJ M, VirtamoJ, FogelholmR, AlbanesD, HeinonenO P. Different risk factors for different stroke subtypes: Association of blood pressure, cholesterol, and antioxidants. Stroke, 1999, 30(12): 2535-2540

[30] ManabeS, OkuraT, WatanabeS, HigakiJ. Association between carotid haemodynamics and inflammation in patients with essential hypertension. J Hum Hypertens, 2005, 19(10): 787-791

[31] Garanty-BogackaB, SyreniczM, SyreniczA, GebalaA, LulkaD, WalczakM. Serum markers of inflammation and endothelial activation in children with obesity-related hypertension. Neuro Endocrinol Lett, 2005, 26(3): 242-246

Acknowledgements

This research was supported by the Special Funds for Major State Basic Research Program of China (973 Program) (No. G2000056901).

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg